Neural grafting in Parkinson's disease. Unraveling the mechanisms underlying graft-induced dyskinesia

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 295-309

  Lane, Emma L ^a   Björklund, Anders ^b   Dunnett, Stephen B ^a   Winkler, Christian ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Amphetamine induced dyskinesia; Dopamine; Dyskinesia; Graft induced dyskinesia; L dopa induced dyskinesia; Parkinson's disease; Transplantation

Indexed keywords

AMANTADINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA;

BOOK; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; DISEASE SEVERITY; DYSKINESIA; GRAFT REJECTION; HUMAN; HYPERKINESIA; IMMUNOSUPPRESSIVE TREATMENT; NERVE GRAFT; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77957235017     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84015-4     Document Type: Chapter

References (68)

1. Bjorklund A. Dopaminergic transplants in experimental parkinsonism: Cellular mechanisms of graft-induced functional recovery. Current Opinion in Neurobiology 1992, 2:683-689.
2. Carlsson T., Carta M., Munoz A., Mattsson B., Winkler C., Kirik D., et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2008, 132:319-335.
3. Carlsson T., Carta M., Winkler C., Bjorklund A., Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. Journal of Neuroscience 2007, 27:8011-8022.
4. Carlsson T., Winkler C., Lundblad M., Cenci M.A., Bjorklund A., Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of Disease 2006, 21:657-668.
5. Cenci M.A., Hagell P. Dyskinesia and neural grafting in Parkinson's disease. Restorative Therapies in Parkinson's Disease 2006, 184-224.
6. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. European Journal of Neuroscience 1998, 10:2694-2706.
7. Cho C., Alterman R., Miravite J., Shils J., Taglati M. Subthalamic DBS for the treatment of "runaway" dyskinesias after embryonic or fetal tissue transplant. Movement Disorder 2005, 20:1237.
8. Cochen V., Ribeiro M.J., Nguyen J.P., Gurruchaga J.M., Villafane G., Loc'h C., et al. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Movement Disorder 2003, 18:928-932.
9. de la Fuente-Fernandez R., Stoessl A.J. The placebo effect in Parkinson's disease. Trends in Neurosciences 2002, 25:302-306.
10. Defer G.L., Geny C., Ricolfi F., Fenelon G., Monfort J.C., Remy P., et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996, 119(Pt 1):41-50.
11. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model. Behavioural Brain Research 2007, 179:76-89.
12. Freed C., Breeze R., Fahn S., Eidelberg D. Preoperative response to levodopa is the best predictor of transplant outcome. Annals of Neurology 2004, 55:896. -379.
13. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine 2001, 344:710-719.
14. Garcia J.A., Carlsson T., Nikkhah G., Winkler C. Role of dopamine and serotonin grafts for the expression of L-dopa- and graft-induced dyskinesia. Society for Neuroscience Abstracts 2009, 430. 10/I14.
15. Goetz C.G., Wuu J., McDermott M.P., Adler C.H., Fahn S., Freed C.R., et al. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Movement Disorder 2008, 23:690-699.
16. Graff-Radford J., Foote K.D., Rodriguez R.L., Fernandez H.H., Hauser R.A., Sudhyadhom A., et al. Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. Archives of Neurology 2006, 63:1181-1184.
17. Greene P., Fahn S., Tsai W.Y., Breeze R., Eidelberg D., Winfield H., et al. Severe spontaneous dyskinesias: A disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. Movement Disorder 1999, 14:904.
18. Hagell P., Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. Journal of Neuropathology and Experimental Neurology 2001, 60:741-752.
19. Hagell P., Cenci M.A. Dyskinesias and dopamine cell replacement in Parkinson's disease: A clinical perspective. Brain Research Bulletin 2005, 68:4-15.
20. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nature Neuroscience 2002, 5:627-628.
21. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Archives of Neurology 1999, 56:179-187.
22. Herman J.P., Abrous N.D. Dopaminergic neural grafts after fifteen years: Results and perspectives. Progress in Neurobiology 1994, 44:1-35.
23. Herman J.P., Rouge-Pont F., Le Moal M., Abrous D.N. Mechanisms of amphetamine-induced rotation in rats with unilateral intrastriatal grafts of embryonic dopaminergic neurons: A pharmacological and biochemical analysis. Neuroscience 1993, 53:1083-1095.
24. Herzog J., Pogarell O., Pinsker M.O., Kupsch A., Oertel W.H., Lindvall O., et al. Deep brain stimulation in Parkinson's disease following fetal nigral transplantation. Movement Disorder 2008, 23:1293-1296.
25. Jacocks H.M., Cox B.M. Serotonin-stimulated release of [3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: A comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. Journal of Pharmacology and Experimental Therapeutics 1992, 262:356-364.
26. Jacques D.B., Kopyov O.V., Eagle K.S., Carter T., Lieberman A. Outcomes and complications of fetal tissue transplantation in Parkinson's disease. Stereotactic and Functional Neurosurgery 1999, 72:219-224.
27. Kannari K., Shen H., Arai A., Tomiyama M., Baba M. Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neuroscience Letters 2006, 402:62-65.
28. Kelley A.E., Lang C.G., Gauthier A.M. Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. Psychopharmacology 1988, 95:556-559.
29. Kopyov O.V., Jacques D.S., Lieberman A., Duma C.M., Rogers R.L. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. Experimental Neurology 1997, 146:536-545.
30. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine 2008, 14:504-506.
31. Kordower J.H., Chu Y., Hauser R.A., Olanow C.W., Freeman T.B. Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. Movement Disorder 2008, 23:2303-2306.
32. Kordower J.H., Styren S., Clarke M., DeKosky S.T., Olanow C.W., Freeman T.B. Fetal grafting for Parkinson's disease: Expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant 1997, 6:213-219.
33. Kuan W.L., Lin R., Tyers P., Barker R.A. The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiology of Disease 2007, 25:594-608.
34. Lane E.L., Brundin P., Cenci M.A. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiology of Disease 2009, 35:42-51.
35. Lane E.L., Soulet D., Vercammen L., Cenci M.A., Brundin P. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease. Neurobiology of Disease 2008, 32:220-228.
36. Lane E.L., Vercammen L., Cenci M.A., Brundin P. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Experimental Neurology 2009, 219:255-258.
37. Lane E.L., Winkler C., Brundin P., Cenci M.A. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiology of Disease 2006, 22:334-345.
38. Lee C.S., Cenci M.A., Schulzer M., Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000, 123(Pt 7):1365-1379.
39. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine 2008, 14:501-503.
40. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. The European Journal of Neuroscience 2002, 15:120-132.
41. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Annals of Neurology 2002, 52:628-634.
42. Ma Y., Tang C., Chaly T., Greene P., Breeze R., Fahn S., et al. Dopamine cell implantation in Parkinson's disease: Long-term clinical and (18)F-FDOPA PET outcomes. Journal of Nuclear Medicine 2010, 51:7-15.
43. Maries E., Kordower J.H., Chu Y., Collier T.J., Sortwell C.E., Olaru E., et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiology of Disease 2006, 21:165-180.
44. Mendez I., Dagher A., Hong M., Hebb A., Gaudet P., Law A., et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. Journal of Neurosurgery 2000, 92:863-869.
45. Mendez I., Hong M., Smith S., Dagher A., Desrosiers J. Neural transplantation cannula and microinjector system: Experimental and clinical experience. Technical note. Journal of Neurosurgery 2000, 92:493-499.
46. Mendez I., Sanchez-Pernaute R., Cooper O., Vinuela A., Ferrari D., Bjorklund L., et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005, 128:1498-1510.
47. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine 2008, 14:507-509.
48. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology 2003, 54:403-414.
49. Olanow C.W., Gracies J.M., Goetz C.G., Stoessl A.J., Freeman T., Kordower J.H., et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video-based analysis. Movement Disorder 2009, 24:336-343.
50. Piccini P., Brooks D.J., Bjorklund A., Gunn R.N., Grasby P.M., Rimoldi O., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience 1999, 2:1137-1140.
51. Piccini P., Lindvall O., Bjorklund A., Brundin P., Hagell P., Ceravolo R., et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology 2000, 48:689-695.
52. Piccini P., Pavese N., Hagell P., Reimer J., Bjorklund A., Oertel W.H., et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128:2977-2986.
53. Politis M., Wu K., Loane C., Quinn N., Brooks D.J., Rehncrona S., et al. Serotonergic neurons cause "off"-dyskinesias in Parkinson's patients with neural transplants. Science Translational Medicine 2010, 2:38-46.
54. Saldana S.N., Barker E.L. Temperature and 3,4-methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake. Neuroscience Letters 2004, 354:209-212.
55. Schmidt C.J., Lovenberg W. In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat. Neuroscience Letters 1985, 59:9-14.
56. Soderstrom K.E., Meredith G., Freeman T.B., McGuire S.O., Collier T.J., Sortwell C.E., et al. The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors. Neurobiology of Disease 2008, 32:229-242.
57. Steece-Collier K., Soderstrom K.E., Collier T.J., Sortwell C.E., Maries-Lad E. Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. The Journal of Comparative Neurology 2009, 515:15-30.
58. Thompson L., Barraud P., Andersson E., Kirik D., Bjorklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. Journal of Neuroscience 2005, 25:6467-6477.
59. Torres E.M., Dowd E., Dunnett S.B. Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease. Neuroscience 2008, 154:631-640.
60. Torres E.M., Monville C., Gates M.A., Bagga V., Dunnett S.B. Improved survival of young donor age dopamine grafts in a rat model of Parkinson's disease. Neuroscience 2007, 146:1606-1617.
61. Vinuela A., Hallett P.J., Reske-Nielsen C., Patterson M., Sotnikova T.D., Caron M.G., et al. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain 2008, 131:3361-3379.
62. Wenning G.K., Odin P., Morrish P., Rehncrona S., Widner H., Brundin P., et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology 1997, 42:95-107.
63. Winkler C., Garcia J.A., Carlsson T., Nikkhah G. Predictive value of severity of preoperative L-dopa-induced dyskinesia for the development of graft-induced dyskinesia in the rat Parkinson model. Society for Neuroscience Abstracts 2009, 430. 19/I15.
64. Winkler C., Kirik D., Bjorklund A. Cell transplantation in Parkinson's disease: How can we make it work?. Trends in Neurosciences 2005, 28:86-92.
65. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: Relation to motor and cellular parameters of nigrostriatal function. Neurobiology of Disease 2002, 10:165-186.
66. Winkler C., Kirik D., Bjorklund A., Dunnett S.B. Transplantation in the rat model of Parkinson's disease: Ectopic versus homotopic graft placement. Progress in Brain Research 2000, 127:233-265.
67. Yeghiayan S.K., Kelley A.E. Serotonergic stimulation of the ventrolateral striatum induces orofacial stereotypy. Pharmacology Biochemistry and Behavior 1995, 52:493-501.
68. Yeghiayan S.K., Kelley A.E., Kula N.S., Campbell A., Baldessarini R.J. Role of dopamine in behavioral effects of serotonin microinjected into rat striatum. Pharmacology Biochemistry and Behavior 1997, 56:251-259.